In patients with metabolic dysfunction-associated fatty liver disease, the combination of high body roundness index and high systemic immune-inflammation index increased the risk of all-cause mortality by 89% (HR 1.89) compared to those with low indices.
Cohort (n=12,435)
Does the combination of high Body Roundness Index and high Systemic Immune-Inflammation Index predict mortality in patients with MAFLD?
High Body Roundness Index and Systemic Immune-Inflammation Index are independent predictors of all-cause and cardiovascular mortality in patients with MAFLD, suggesting their utility for cardiometabolic risk stratification.
Hazard Ratio: 1.89 (95% CI 1.62–2.21)
p-value: p=<0.0001
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a major cause of liver-related morbidity and mortality, contributing to both cardiovascular and non-cardiovascular deaths. The Body Roundness Index (BRI) and Systemic Immune-Inflammation Index (SII) have emerged as predictors of adverse outcomes in metabolic diseases. This study investigates the association between BRI, SII, and mortality risk in MAFLD patients. A nationwide retrospective cohort study was conducted using data from the NHANES database (January 1999-December 2018), including patients diagnosed with MAFLD. BRI and SII were calculated at baseline. Cox proportional hazards models assessed the association between these indices and all-cause, cardiovascular, and non-cardiovascular mortality, adjusting for confounders. Among 12,435 participants diagnosed with MAFLD, 3,381 (27.2%) were classified into the low BRI and low SII group, 2,889 (23.2%) into the low BRI and high SII group, 2,802 (22.5%) into the high BRI and low SII group, and 3,363 (27.1%) into the high BRI and high SII group. Compared to the low BRI and low SII group, the high BRI and high SII group demonstrated significantly higher all-cause mortality, with an adjusted hazard ratio (HR) of 1.89. For cardiovascular mortality, the HR was 2.31, while for non-cardiovascular mortality, the HR was 1.78. The high BRI and high SII cohort exhibited the highest risk of all-cause mortality, cardiovascular mortality, and non-cardiovascular mortality. BRI and SII are independent predictors of mortality in MAFLD patients, and their combined use enhances risk stratification. Integrating these indices into clinical practice could improve personalized management strategies and outcomes in this high-risk population.
Zeng et al. (Thu,) conducted a cohort in Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) (n=12,435). High Body Roundness Index (BRI) and high Systemic Immune-Inflammation Index (SII) vs. Low BRI and low SII was evaluated on All-cause mortality (HR 1.89, 95% CI 1.62-2.21, p=<0.0001). In patients with metabolic dysfunction-associated fatty liver disease, the combination of high body roundness index and high systemic immune-inflammation index increased the risk of all-cause mortality by 89% (HR 1.89) compared to those with low indices.